Catalyst Pharmaceuticals (CPRX) 10-Q2023 Q2 Quarterly report

Filed: 9 Aug 23, 4:07pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: accounti, adequately, adolescent, advance, affirmative, ambulation, binding, birth, candidate, cardiac, cardiomyopathy, CEO, Chairman, characterized, CHF, childhood, committee, decade, defense, degeneration, differentiated, dissociate, dissociated, dissociative, DMD, downstream, Duchenne, dystrophy, endpoint, Europe, exhaustive, failure, firm, footprint, franchise, geographical, incomplete, incorporate, inflammation, inherited, keen, male, manifested, McEnany, mechanism, mid, mode, muscle, muscular, mutually, ng, oversee, overthe, partnership, Patrick, PDUFA, PMDA, preliminary, prevalence, progressive, reapproved, replacement, respiratory, Santhera, serve, showed, split, Stand, steering, steroid, synergy, theCompany, theShare, tied, tolerability, Track, TTSTAND, underRule, unmet, USD, User, vamorolone, velocity, ventilation

Removed: accomplish, border, broaden, broader, build, carcinogenicity, contact, deficit, disrupt, diversified, diversify, employing, evidence, flawed, implemented, issuance, issuing, legally, mask, Monograph, nonclinical, overturn, phosphate, quashed, redetermine, regulation, relied, remotely, reproductive, ruling, setting, submission, supported, supposed, toxicity, varying

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Associated CPRX transcripts

CPRX similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.2

Certification Required by 18 U.S.C. Section 1350

(as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002)

I, Alicia Grande as Principal Financial Officer of Catalyst Pharmaceuticals, Inc. (the Company), certify, pursuant to 18 U.S.C. Section 1350 (as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002), that to my knowledge:

1.	the accompanying Quarterly Report on Form 10-Q of the Company for the quarterly period ended June 30, 2023 (the Report), filed with the U.S. Securities and Exchange Commission, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

2.	the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Date: August 9, 2023		/s/ Alicia Grande
		Alicia Grande
		Chief Financial Officer
		(Principal Financial Officer)

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.